FGHQF(FGHQF)

$0.17—Stale · unknown old

Ask SA Chart

FGHQF(FGHQF)

OTC • Last print unknown ago

$0.17—Stale · unknown old

Ask SA Chart Studio

FGHQF(FGHQF)

FGHQF

9/16/26

Frontage (FGHQF)

Wednesday

6:09 AM

ThesisThe recent contract wins and expansion plans in China are positioning Frontage for significant revenue growth, enhancing investor sentiment.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$257M	$298M	$327M
Rev. Growth	+0.8%	+15.7%	+9.9%
EPS	$0.00	$0.01	$0.01
EPS Growth	+750%	+217%	+7.5%
P/E (fwd)	51.5×	16.2×	15.1×

★ Analysts see FY2026 revenue reaching $298M — +15.7% growth in a single year.

Why Revenue Could Accelerate

01Frontage has secured a multi-year contract with a leading pharmaceutical company worth $50 million, enhancing its revenue visibility.
02The company is expanding its laboratory capacity in China, which is projected to increase revenue from the region by 20% over the next year.
03Recent regulatory approvals for key drug trials in the U.S. could lead to a surge in demand for Frontage's clinical services.
04The company's gross margin has improved by 5% YoY due to operational efficiencies, indicating better cost management.
05Increased outsourcing of drug development processes
06Growth in biotech funding and innovation
07New client contracts in the U.S. and China
08Regulatory approvals for drug trials

FY2025 Snapshot

Revenue: $257M
Rev. Growth: +0.8%
Gross Margin: 27.0%
Op. Margin: 5.7%
Net Margin: 2.6%
Net Income: $7M
NI Growth: +760%
EPS: $0.00
1Y Return: +16.8%

FGHQF Chart

My Notes

"Our strategic investments and new partnerships are setting the stage for robust growth in the coming years."
Moat: Frontage's integrated service model and strong relationships with clients provide a durable competitive advantage in the CRO market.
growth - Investors looking for exposure to the expanding biotech sector and CRO market.
Higher interest rates can increase the cost of financing for Frontage's clients…
Watch on earnings: New contract value, Client retention rate, Gross margin trends.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $298M to $327M as frontage has secured a multi-year contract with a leading pharmaceutical company worth $50 million.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

51.5×

16.2×

15.1×

Why Revenue Could Accelerate

01Frontage has secured a multi-year contract with a leading pharmaceutical company worth $50 million, enhancing its revenue visibility.

02The company is expanding its laboratory capacity in China, which is projected to increase revenue from the region by 20% over the next year.

03Recent regulatory approvals for key drug trials in the U.S. could lead to a surge in demand for Frontage's clinical services.

04The company's gross margin has improved by 5% YoY due to operational efficiencies, indicating better cost management.

05Increased outsourcing of drug development processes

06Growth in biotech funding and innovation

07New client contracts in the U.S. and China

08Regulatory approvals for drug trials

My Notes

"Our strategic investments and new partnerships are setting the stage for robust growth in the coming years."

Moat: Frontage's integrated service model and strong relationships with clients provide a durable competitive advantage in the CRO market.

growth - Investors looking for exposure to the expanding biotech sector and CRO market.

Higher interest rates can increase the cost of financing for Frontage's clients…

Watch on earnings: New contract value, Client retention rate, Gross margin trends.